How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,224 results for

Tongue Carcinoma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1681. Anesthesia and ventilation options for flex robotic assisted laryngopharyngeal surgery. (Abstract)

Anesthesia and ventilation options for flex robotic assisted laryngopharyngeal surgery. Transoral treatment of benign and malignant lesions of laryngopharynx has limitations in exposure and access, partially due to the endotracheal tube (ETT). With a proper airway control to tailor ventilation and maximize exposure, transoral Flex robotic surgery (FLEX), using its 3D camera and instruments, can expand its ability. Choosing the right ETT, including a novel concept of using jet ventilation (JV (...) indications for trans-oral robotic surgery including the feasibility of JV in FLEX procedures were shown.Lesions of the tongue base, hypopharynx, larynx and trachea have the possibility to be managed with adequate exposure with minimal obstruction from ETT. Robotic HD camera permits both the surgeon and anesthesiologist to observe surgery and safely monitor the airway. An algorithm was developed for selecting ideal ventilation method for different procedures. The FLEX and the utilization of JV allows

2019 American Journal of Otolaryngology

1682. Total Glossectomy With Free Flap Reconstruction: Twenty-Year Experience at a Tertiary Medical Center. (Abstract)

31, 2014 were included in the analysis. Patient characteristics and clinical outcomes were reviewed.Forty-eight patients underwent total glossectomy for oral tongue and base of tongue cancer. The mean age of the patients was 56 (range, 29-92 years). History of tobacco and heavy alcohol use was found in 76% and 11% of patients, respectively. The majority of patients had advanced cancer (91.7% at stage IV), and 60.4% had salvage therapy for recurrent disease. T4 disease comprised 81% of patients (...) . Sixty percent had clinical or radiographic evidence of nodal metastasis. Reconstruction of the defect was performed with free flaps from the rectus abdominus (40%), fibula (25%), anterolateral thigh (23%), and other donor tissues. One- and 5-year survival rates were 42% and 26%, with locoregional and distant recurrence reported at 36% and 25%, respectively.Total glossectomy for oncologic control is most commonly performed in patients who have stage IV cancers. Despite high reconstructive success

2019 Laryngoscope

1683. Syphilis of the oropharynx: Case series of "The Great Masquerader". (Abstract)

Syphilis of the oropharynx: Case series of "The Great Masquerader". Syphilis is a sexually transmitted infection with various presentations. Although, oropharyngeal manifestations are known to occur, the purpose of this study is to present the first case series in which the lesions were initially mistaken for human-papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC).A multi-institutional retrospective review.Six cases of oropharyngeal syphilis were initially thought (...) to be secondary to OPSCC due to presentation. Symptoms were vague and exam findings consisted of either a tonsillar or base of tongue mass, or lymphadenopathy. Biopsies were negative for OPSCC. Further workup diagnosed syphilis, with resolution of symptoms and lesions after antibiotic treatment.Head and neck manifestations of syphilis have been reported in the literature. However, this is the first series reporting on oropharyngeal syphilis masquerading as HPV-related OPSCC. Ultimately, otolaryngologists must

2019 American Journal of Otolaryngology

1684. Diagnosis and Treatment of Pituitary Adenomas: A Review. (Abstract)

, and radiotherapy. Prolactinomas account for 32% to 66% of adenomas and present with amenorrhea, loss of libido, galactorrhea, and infertility in women and loss of libido, erectile dysfunction, and infertility in men; they are generally treated with the dopamine agonists cabergoline and bromocriptine. Growth hormone-secreting tumors account for 8% to 16% of tumors and usually present with enlargement of the lips, tongue, nose, hands, and feet and are diagnosed by elevated insulin-like growth factor 1 levels (...) . The primary treatment of Cushing disease (hypercortisolism due to ACTH-producing adenomas, which is the cause in approximately 65% of the cases of hypercortisolism) is adenoma resection and medical therapies including ketoconazole, mifepristone, and pasireotide. Hyperthyroidism due to thyroid-stimulating hormone-secreting tumors accounts for 1% of tumors and is treated with surgery and somatostatin analogues if not surgically cured. Clinically nonfunctioning adenomas account for 15% to 54% of adenomas

2017 JAMA

1685. Ectopic thyroid in the gallbladder accompanied with gallbladder adenoma: A case report. Full Text available with Trip Pro

Ectopic thyroid in the gallbladder accompanied with gallbladder adenoma: A case report. Ectopic thyroid is most common in the tongue. Here we reported a rare case of thyroid tissue located in the gallbladder wall, accompanied with adenoma and a cyst lined with pseudostratified ciliated columnar epithelium in the neck region of gallbladder neck.A 39-year-old female presented with recurrent upper abdominal pain and radiating back pain.Based on ultrasonography, gallbladder polyps and calculous (...) malignancy to avoid unnecessary overtreatment.

2019 Medicine

1686. Dysphagia Rehabilitation for Nasopharyngeal Carcinoma Patients Post Radiotherapy

should provide justification for rehabilitation time, clinicians' efforts, costs involved and resources used in rehabilitating the swallowing difficulties of the NPC patients. Condition or disease Intervention/treatment Phase Nasopharyngeal Carcinoma Radiotherapy Behavioral: Traditional rehabilitation (TR) Behavioral: Transcutaneous electrical stimulation (ES) Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 160 (...) to Layout table for additonal information Responsible Party: Michael Tong, Professor, Chinese University of Hong Kong ClinicalTrials.gov Identifier: Other Study ID Numbers: GRF 475210 First Posted: November 10, 2010 Last Update Posted: February 26, 2013 Last Verified: February 2013 Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Nasopharyngeal Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Nasopharyngeal Neoplasms Pharyngeal Neoplasms

2010 Clinical Trials

1687. Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma

visits for tests 1 day and 1 week after the end of rapamycin treatment, followed by HNSCC surgery. Participants will have a final visit to provide blood samples 30 days after surgery. Participants medical records will be reviewed 1 year after surgery; however, participants will not need to have further study visits at this time. Condition or disease Intervention/treatment Phase Mouth Neoplasms Head and Neck Neoplasms Tongue Neoplasms Carcinoma, Squamous Cell Drug: Sirolimus Phase 1 Phase 2 Study (...) for MeSH terms Carcinoma Neoplasms Carcinoma, Squamous Cell Squamous Cell Carcinoma of Head and Neck Head and Neck Neoplasms Mouth Neoplasms Tongue Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms, Squamous Cell Neoplasms by Site Mouth Diseases Stomatognathic Diseases Tongue Diseases Sirolimus Everolimus Anti-Bacterial Agents Anti-Infective Agents Antibiotics, Antineoplastic Antineoplastic Agents Antifungal Agents Immunosuppressive Agents Immunologic Factors

2010 Clinical Trials

1688. Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma

of tumor cells by blocking some of the enzymes needed for cell growth. Condition or disease Intervention/treatment Phase Recurrent Oral Cavity Adenoid Cystic Carcinoma Recurrent Salivary Gland Carcinoma Salivary Gland Adenoid Cystic Carcinoma Stage III Major Salivary Gland Cancer AJCC v7 Stage III Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7 Stage IVA Major Salivary Gland Cancer AJCC v7 Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7 Stage IVB Major Salivary Gland Cancer AJCC v7 (...) Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7 Stage IVC Major Salivary Gland Cancer AJCC v7 Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7 Tongue Carcinoma Other: Laboratory Biomarker Analysis Drug: Vorinostat Phase 2 Detailed Description: PRIMARY OBJECTIVES: I. To evaluate the efficacy by means of response rate (based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) of vorinostat in the treatment of patients with locally advanced, recurrent

2010 Clinical Trials

1689. Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract

) pathology will be used to see whether both tests tended to agree on diagnoses. Condition or disease Intervention/treatment Phase Upper Aerodigestive Tract Lesions Neoplasms, Oropharyngeal Oropharyngeal Cancer Neoplasms, Hypopharyngeal Hypopharyngeal Cancer Head and Neck Neoplasms UADT Neoplasms Carcinoma, Squamous Cell Papilloma Device: Direct Rigid Endoscopy Device: Transnasal Flexible Endoscopy with Narrowband Imaging Not Applicable Study Design Go to Layout table for study information Study Type (...) Comprehensive Cancer Center ) First Posted: August 4, 2010 Last Update Posted: August 19, 2014 Last Verified: August 2014 Keywords provided by University of California, San Francisco: laryngoscopy Laryngoscopic Surgery laryngoscopes upper aerodigestive tract lesions endoscopy biopsy Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Neoplasms Papilloma Head and Neck Neoplasms Oropharyngeal Neoplasms Carcinoma, Squamous Cell Hypopharyngeal Neoplasms Neoplasms, Glandular and Epithelial

2010 Clinical Trials

1690. Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)

Therapeutics ClinicalTrials.gov Identifier: Other Study ID Numbers: VT1-CAX-200 First Posted: December 23, 2010 Last Update Posted: December 9, 2015 Last Verified: December 2015 Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma, Hepatocellular Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Digestive System Diseases Liver Diseases Sorafenib Etodolac Propranolol Antineoplastic (...) specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, for any reason without prejudice. Exclusion Criteria: Participants must not have any of the following criteria to be considered eligible for inclusion in the study: The patient has a history of another primary cancer, with the exception of: a) curatively resected non-melanomatous skin cancer; b) curatively treated cervical carcinoma in-situ; or c) other primary solid tumor

2010 Clinical Trials

1691. Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma

palate, base of tongue, lateral and posterior pharyngeal wall Patient must be AJCC (American Joint Committee on Cancer) Stage III (T3N0, T1-2N1) or Stage IVa (T1-4N2-3M0, T4N0-1 M0) and be either unresectable or borderline resectable No prior therapy for the tumor, including extensive surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy or any other investigational agents; surgical biopsy prior to beginning the study is allowable Prior malignancies at sites other than the head (...) and neck are allowable if there has been greater than or equal to a 3 year disease free interval; basal cell carcinoma of the skin and in-situ cervix dysplasias are allowable within this 3 year interval if completely resected There must be documentation of evaluable tumor within four weeks of beginning therapy ECOG (Eastern Cooperative Oncology Group) Performance Status 0-2, (Karnofsky > 60%) Ability to understand and the willingness to sign a written informed consent Patient must have normal liver

2010 Clinical Trials

1692. Surgery and postoperative radiotherapy a valid treatment for advanced oropharyngeal carcinoma Full Text available with Trip Pro

our treatment policy for tonsillar and base of tongue carcinoma. We first changed the treatment for the lesions with worst prognosis, i.e., those with T3-T4 carcinomas, from radiotherapy only, to radical surgery and postoperative radiotherapy. We have since that time increasingly also operated the smaller oropharyngeal carcinomas. The 2 years' overall survival and disease-specific survival for all patients diagnosed in the 1992-1997 period was 56 and 63%, respectively. The results from a similar (...) Surgery and postoperative radiotherapy a valid treatment for advanced oropharyngeal carcinoma Since 1992 we have prospectively included all head and neck cancer patients in our health region in a departmental based register. Our hospital takes care of all head and neck cancer patients in our health region consisting of approximately 1 million people. In 1997, we evaluated the results of the treatment of oropharyngeal cancer in the 1992-1997 period. On the basis of this evaluation, we changed

2010 European Archives of Oto-Rhino-Laryngology

1693. Papillary carcinoma arising in a submentalintralingual thyroglossal duct cyst Full Text available with Trip Pro

Papillary carcinoma arising in a submentalintralingual thyroglossal duct cyst An extremely rare case of papillary carcinoma is described arising in a submental-intralingual thyroglossal duct cyst. A 27-year-old male presented with a painless swelling in the submental region extending to the tongue which had gradually been increasing in size over the last three months. Upon examination of the neck, a tender right paramedian mass was found in the submental region just above the hyoid bone (...) , it was mobile upon swallowing without clinical evidence of cervical nodes. The Sistrunk surgical technique, extended to the submental and intra lingual region was used to radically remove the mass. The occurrence of carcinoma of the thyroglossal duct cyst, even though rare and unexpected, should always be considered an option, and histologically ruled out mainly on account of the atypical localization, such as the submental-intralingual reported herein. The two different surgical approaches reported

2010 Acta Otorhinolaryngologica Italica

1694. The Impact of Adjuvant Radiotherapy on Survival in T1-2N1 Squamous Cell Carcinoma of the Oral Cavity. Full Text available with Trip Pro

survival in patients with T1-2N1 OCSCC.Postoperative RT improved the 5-year overall survival rate (41.4% for surgery alone vs 54.2% for surgery plus RT [P < .001]). Improvement in overall survival in patients with T1N1 disease did not achieve statistical significance with the addition of RT in contradistinction to that in patients with T2N1 disease. Adjuvant RT improved survival in patients with T2 tongue and floor of mouth disease (52.3% vs 37.9% [P = .002] and 39.9% vs 17.7% [P = .003], respectively (...) ).In cases involving T1-2N1 OCSCC in the Surveillance, Epidemiology, and End Results database, the use of RT is associated with statistically significant improved overall survival and cause-specific survival in patients with T2 disease, most strongly in the oral tongue and the floor of the mouth.

2010 Archives of Otolaryngology Head and Neck Surgery

1695. Multiple squamous cell carcinomas of the oral cavity in a young patient with graft-versus-host disease following allogenic bone marrow transplantation. (Abstract)

Multiple squamous cell carcinomas of the oral cavity in a young patient with graft-versus-host disease following allogenic bone marrow transplantation. The development of secondary malignancies is a potential long-term complication after haematopoietic stem cell transplantation (HSCT). In particular, a higher incidence of oral squamous cell carcinoma (OSCC) has been reported in patients experiencing chronic graft versus host disease (cGvHD) secondary to HSCT. This report describes (...) the development of two synchronous SCC of the buccal mucosa in a young female patient treated with HSCT for beta thalassemia major. She had undergone HSCT at the age of 9 years and developed oral GvHD 6 months after transplant. 17 years after HSCT she developed two synchronous carcinomatous lesions on the tongue and floor of the mouth. The current case highlights the association between oral cGvHD and OSCC, and the possible development of OSCC in young patients even many years after HSCT. This evidence

2010 International Journal of Oral and Maxillofacial Surgery

1696. Population-based analysis of oral and oropharyngeal carcinoma: Changing trends of histopathologic differentiation, survival and patient demographics. (Abstract)

Population-based analysis of oral and oropharyngeal carcinoma: Changing trends of histopathologic differentiation, survival and patient demographics. To examine demographic, histologic, and survival trends of oral cavity and oropharyngeal (OC/OP) squamous cell carcinoma (SCCA) patients over the past 3 decades. To test the hypothesis that decreased histologic differentiation and increased disease-specific survival is related to a decline in smoking rates and an increased percentage of human (...) papillomavirus (HPV)-related tumors.Retrospective cohort analysis was done using the Surveillance, Epidemiology, and End-Results (SEER) database of the national cancer institute.SEER data were used to design seven cohorts: 1975-1979, 1980-1984, 1985-1989, 1990-1994, 1995-1999, 2000-2004, and 2005-2006. Incidence rates, histologic tumor grade. and 5-year survival rates were analyzed over time. Further subgroup analysis was performed according to subsite, age, gender, and stage.In both OC and OP, well

2010 Laryngoscope

1697. Cannabis and Cannabinoids (PDQ®): Health Professional Version

to treat malignant lymphoblastic disease. Blood 100 (2): 627-34, 2002. [ ] Casanova ML, Blázquez C, Martínez-Palacio J, et al.: Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111 (1): 43-50, 2003. [ ] [ ] Blázquez C, González-Feria L, Alvarez L, et al.: Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64 (16): 5617-23, 2004. [ ] Guzmán M: Cannabinoids: potential anticancer agents. Nat Rev Cancer 3 (...) lines, CBD upregulated ICAM-1, leading to decreased cancer cell invasiveness. In an in vivo model using severe combined immunodeficient mice, subcutaneous tumors were generated by inoculating the animals with cells from human non-small cell lung carcinoma cell lines.[ ] Tumor growth was inhibited by 60% in THC-treated mice compared with vehicle-treated control mice. Tumor specimens revealed that THC had and antiproliferative effects. However, research with murine has demonstrated and enhanced tumor

2017 PDQ - NCI's Comprehensive Cancer Database

1698. Ryzodeg - insulin degludec / insulin aspart

AUC area under the curve BB basal–bolus BID twice daily BMI body mass index C max maximum plasma concentration CGM continuous glucose monitoring CHMP Committee for Medicinal Products for Human Use CI confidence interval CSII continuous subcutaneous insulin infusion CV coefficient of variation CYP cytochrome P450 DPP-4 inhib dipeptidyl peptidase-4 inhibitor ECG electrocardiogram ELISA enzyme-linked immuno sorbent assay ESRD end-stage renal disease FAS full analysis set FF fixed flexible FPG fasting (...) in the abdominal wall, the upper arm or the thigh. IDegAsp is developed to cover basal insulin needs in patients with diabetes mellitus from early to late stages of the disease, either alone or in combination with bolus insulin as well as oral antidiabetic drugs. For patients with type 2 diabetes mellitus, the recommended total daily starting dose of IDegAsp is 10 units with meal(s) followed by individual dosage adjustments. For patients with type 1 diabetes mellitus, IDegAsp is to be used once-daily at meal

2013 European Medicines Agency - EPARs

1699. Erivedge - vismodegib

, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a conditional Marketing Authorisation to Erivedge on 25 April 2013. 2. Scientific discussion 2.1. Introduction Basal Cell Cancer or Basal Cell Carcinoma (BCC) is a slow-growing, locally invasive, malignant epidermal skin tumour predominantly affecting Caucasians. Although it is the most common malignancy worldwide, it is very difficult to estimate the incidence (...) as an important signalling pathway in human cancers. Mutations in components of the Hh pathway has been identified both in basal cell carcinoma and medulloblastoma, but are also implicated in the development of other cancer such as lung, breast and pancreas 6,8 . In basal cell carcinoma a high frequency (about 90%) of inactivating mutations in PTCH1 or to a lesser extent (about 10%) activating mutations in SMO is identified. Vismodegib is a small molecule inhibitor of the Hh signalling pathway, which acts

2013 European Medicines Agency - EPARs

1700. Fortacin - lidocaine / prilocaine

in the intended indication is limited to one year, concerns regarding the potential systemic risks (e.g. methaemoglobinaemia, systemic malignancies) and carcinogenicity potential were raised. These concerns were adequately addressed by the Applicant. Overall, the potential occurrence of methaemoglobinaemia from prilocaine and carcinogenicity risk from o-toluidine is extremely unlikely based upon the clinical and non-clinical information provided by the Applicant. The presence of DNA adducts and haemoglobin (...) was not genotoxic and the carcinogenic potential of lidocaine has not been studied. The lidocaine metabolite 2,6-xylidine has genotoxic potential in vitro. In a carcinogenicity study of rats exposed to 2,6-xylidine in utero, postnatally and throughout their lifetime, tumours in the nasal cavity, subcutaneous tumours and liver tumours were observed. The clinical relevance of tumour findings in relation to short-term/intermittent use of lidocaine in humans is unknown. Human exposure from Lidocaine/Prilocaine

2013 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>